1. TMPRSS2-ERG status in circulating tumor cells as predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate;Danila;Eur Urol,2011
2. MOU 225–06-8001: memorandum of understanding between the Food and Drug Administration and the National Cancer Institute and the Center for Medicare and Medicaid Services for the FDA/NCI/CMS Oncology Biomarker Qualification Initiative. Silver Spring, MD: US Food and Drug Administration; 2006. http://www.fda.gov/AboutFDA/PartnershipsCollaborations/MemorandaofUnderstanding-MOUs/DomesticMOUs/ucm115681.htm. Updated April 30, 2009.
3. Circulating tumor cells as biomarkers in prostate cancer;Danila;Clin Cancer Res,2011
4. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases;Allard;Clin Cancer Res,2004
5. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer;Shaffer;Clin Cancer Res,2007